NYSEAMERICAN:PTNPalatin Technologies Stock Price, Forecast & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Palatin Technologies.

Palatin Technologies is scheduled to release its next quarterly earnings announcement on Thursday, September 10th 2020. View our earnings forecast for Palatin Technologies.

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) issued its quarterly earnings results on Tuesday, May, 12th. The biopharmaceutical company reported ($0.02) EPS for the quarter, hitting the consensus estimate of ($0.02). During the same quarter last year, the firm posted ($0.03) EPS. View Palatin Technologies' earnings history.

2 equities research analysts have issued 1-year price targets for Palatin Technologies' shares. Their forecasts range from $2.00 to $6.00. On average, they anticipate Palatin Technologies' stock price to reach $4.00 in the next year. This suggests a possible upside of 667.2% from the stock's current price. View analysts' price targets for Palatin Technologies.

Media stories about PTN stock have been trending negative recently, according to InfoTrie Sentiment. The research group scores the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Palatin Technologies earned a news impact score of -2.0 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutPalatin Technologies.

Palatin Technologies saw a decline in short interest during the month of April. As of April 15th, there was short interest totaling 15,870,000 shares, a decline of 8.3% from the March 31st total of 17,300,000 shares. Based on an average daily volume of 1,480,000 shares, the short-interest ratio is currently 10.7 days. Approximately 7.4% of the company's shares are short sold. View Palatin Technologies' Current Options Chain.

Some companies that are related to Palatin Technologies include Volpara Health Tech (VHT), Profound Medical (PRN), Renalytix Ai (RENX), Akumin (AKU), Exagen (XGN), Yourgene Health (YGEN), Senseonics (SENS), MaxCyte (MXCT), Oncosil Medical (OSL), Lexagene (LXG), Oncimmune (ONC), Genedrive (GDR), SQI Diagnostics (SQD), BARD1 Life Sciences (BD1) and Sernova (SVA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Palatin Technologies investors own include 22nd Century Group (XXII), Heat Biologics (HTBX), Alliqua Biomedical (ALQA), AcelRx Pharmaceuticals (ACRX), AVEO Pharmaceuticals (AVEO), ImmunoGen (IMGN), Progenics Pharmaceuticals (PGNX), Catalyst Pharmaceuticals (CPRX), Novavax (NVAX) and Sorrento Therapeutics (SRNE).

Palatin Technologies trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PTN."

Palatin Technologies' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.70%), Acadian Asset Management LLC (2.37%), State Street Corp (1.61%), Geode Capital Management LLC (1.25%), WINTON GROUP Ltd (0.33%) and Bank of New York Mellon Corp (0.27%). Company insiders that own Palatin Technologies stock include Alan W Dunton, Arlene Morris, Carl Spana, Joseph Stanley Hull, Robert K Deveer Jr and Stephen T Wills. View institutional ownership trends for Palatin Technologies.

PTN stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, BlackRock Inc., Morgan Stanley, UBS Group AG, First Trust Advisors LP, and Banque Cantonale Vaudoise. View insider buying and selling activity for Palatin Technologies.

PTN stock was purchased by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Geode Capital Management LLC, Wells Fargo & Company MN, State Street Corp, Parametric Portfolio Associates LLC, JPMorgan Chase & Co., Two Sigma Advisers LP, and SG Americas Securities LLC. Company insiders that have bought Palatin Technologies stock in the last two years include Alan W Dunton, Arlene Morris, Carl Spana, Joseph Stanley Hull, Robert K Deveer Jr, and Stephen T Wills. View insider buying and selling activity for Palatin Technologies.

Shares of PTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PTN stock can currently be purchased for approximately $0.52.

Palatin Technologies has a market capitalization of $119.54 million. Palatin Technologies employs 19 workers across the globe.

The official website for Palatin Technologies is www.palatin.com.

Palatin Technologies' mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The biopharmaceutical company can be reached via phone at +1-609-4952200.